Cefdinir and Actemra drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cefdinir (cefdinir) and Actemra (tocilizumab). Common drug interactions include pain among females and influenza among males.

The phase IV clinical study analyzes what interactions people have when they take Cefdinir and Actemra. It is created by eHealthMe based on reports of 28 people who take the same drugs from the FDA, and is updated regularly.

What is Cefdinir?

Cefdinir has active ingredients of cefdinir. It is often used in sinusitis. eHealthMe is studying from 9,210 Cefdinir users. Check the latest studies of Cefdinir.

What is Actemra?

Actemra has active ingredients of tocilizumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 102,759 Actemra users. Check the latest studies of Actemra.

On Jul, 12, 2026

28 people who take Cefdinir and Actemra together, and have interactions are studied.

What are the common drug interactions of Cefdinir and Actemra, by gender? *:

female:

Pain
Arthralgia (joint pain)
Urinary tract infection
Blindness
Bone loss
Headache (pain in head)
Rash
Wound infection
Drug ineffective
Pneumonia

male:

Influenza
Juvenile arthritis (arthritis-related condition that develops in children or teenagers)
Blood fibrinogen decreased
Blood immunoglobulin g decreased
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection)
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection)
Platelet count increased
Pulmonary fibrosis (formation or development of excess fibrous connective tissue (fibrosis) in the lungs)
Staphylococcal infection (an infection with staphylococcus bacteria)
Arthralgia (joint pain)

What are the common drug interactions of Cefdinir and Actemra, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Influenza
Juvenile arthritis (arthritis-related condition that develops in children or teenagers)
Stomatitis (inflammation of mucous membrane of mouth)
Upper respiratory tract inflammation
White blood cell count decreased
Lymphadenitis (inflammation or enlargement of a lymph node)
Histiocytosis haematophagic
Tooth infection
Actinomyces test positive
Blood fibrinogen decreased

10-19:

Dysphagia (a condition in which swallowing is difficult or painful)
Encephalopathy (functioning of the brain is affected by some agent or condition)
Pneumonia respiratory syncytial viral (respiratory syncytial virus (rsv) is a very common virus that leads to mild, cold-like symptoms in adults and older healthy children)
Somnolence (a state of near-sleep, a strong desire for sleep)
Pneumonia

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Pain
Drug ineffective
Fatigue (feeling of tiredness)
Upper respiratory tract infection
Arthralgia (joint pain)
Asthma
Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)

60+:

Arthralgia (joint pain)
Blindness
Gait disturbance
Infection
Interstitial lung disease
Limb discomfort (discomfort in leg)
Localised infection (infection at the single location)
Necrotising fasciitis (an uncommon life-threatening soft-tissue infection)
Wound complication
Wound necrosis (damaged cell of wound)

What are the existing conditions these people have? *

Juvenile Arthritis (arthritis-related condition that develops in children or teenagers): 5 people, 17.86%
White Blood Cell Count Decreased: 3 people, 10.71%
Rashes (redness): 3 people, 10.71%
Itching: 3 people, 10.71%
Interleukin Level Increased: 3 people, 10.71%
High Blood Pressure: 3 people, 10.71%
Glaucoma (increased fluid pressure in the eye with vision loss): 3 people, 10.71%
Fever: 3 people, 10.71%
Anal Erosion: 3 people, 10.71%
Adult T-Cell Lymphoma/leukaemia (cancer of the immune system's own t-cells): 3 people, 10.71%

* Approximation only. Some reports may have incomplete information.

Do you take Cefdinir and Actemra?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously